Revenue Recognition

3 Months Ended

Mar. 28, 2020

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

Revenue is recognized when or as a customer obtains control of promised products. The amount of revenue recognized reflects the consideration we expect to be entitled to receive in exchange for these products.

Disaggregation of Revenue

We generated net sales in the following geographic locations⁽¹⁾(in millions):



	Three Months Ended
	March 28, 2020		March 30, 2019
U.S.	$	901.6	$	768.8
Europe⁽²⁾	372.6		340.9
All other countries⁽³⁾	66.8		64.8
Total net sales	$	1,341.0	$	1,174.5

(1) Derived from the location of the entity that sells to a third party.

(2) Includes Ireland net sales of $3.8 million and $5.2 million for the three months ended March 28, 2020 and March 30, 2019, respectively.

(3) Includes net sales generated primarily in Israel, Mexico, Australia and Canada.

Product Category

We re-aligned our product categories in our CSCA and CSCI segments as of December 31, 2019. The re-alignment standardizes our categories and product level detail to provide consistency. This transformative step will optimize the way in which management reports and evaluates our business.

The following is a summary of our net sales by category (in millions); the comparative period reflects the product category re-alignment:



	Three Months Ended
	March 28, 2020		March 30, 2019
CSCA⁽¹⁾
Upper respiratory	$	154.6	$	132.8
Pain and sleep-aids	120.4		91.3
Digestive health	106.9		102.3
Nutrition	102.2		99.6
Healthy lifestyle	85.8		76.0
Oral self-care	55.3		—
Skincare and personal hygiene	46.7		45.5
Vitamins, minerals, and supplements	6.4		6.3
Animal health	—		19.6
Other CSCA⁽²⁾	22.3		8.4
Total CSCA	700.6		581.8
CSCI
Skincare and personal hygiene	94.7		101.9
Upper respiratory	84.1		71.9
Vitamins, minerals, and supplements	48.5		45.8
Pain and sleep-aids	46.8		40.4
Healthy lifestyle	43.6		47.3
Oral self-care	23.2		1.6
Digestive health	6.0		7.2
Other CSCI⁽³⁾	35.8		34.7
Total CSCI	382.7		350.8
RX	257.7		241.9
Total net sales	$	1,341.0	$	1,174.5

(1) Includes net sales from our OTC contract manufacturing business.


(2)	Consists primarily of diagnostic products and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.


(3)	Consists primarily of liquid licensed products, our distribution business and other miscellaneous or otherwise uncategorized product lines and markets, none of which is greater than 10% of the segment net sales.

While the majority of revenue is recognized at a point in time, certain of our product revenue is recognized on an over time basis. Predominately, over time customer contracts exist in contract manufacturing arrangements, which occur in both the CSCA and CSCI segments. Contract manufacturing revenue was $49.5 million and $67.3 million for the three months ended March 28, 2020 and March 30, 2019, respectively.

We also recognize a portion of the store brand OTC product revenues in the CSCA segment on an over time basis; however, the timing difference between over time and point in time revenue recognition for store brand contracts is not significant due to the short time period between the customization of the product and shipment or delivery.

Contract Balances

The following table provides information about contract assets from contracts with customers (in millions):



	Balance Sheet Location	March 28, 2020		December 31, 2019
Short-term contract assets	Prepaid expenses and other current assets	$	28.1	$	26.3